Cover Image
Market Research Report

Global Peptic Ulcer Drugs Market 2017-2021

Published by TechNavio (Infiniti Research Ltd.) Product code 310426
Published Content info 84 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Peptic Ulcer Drugs Market 2017-2021
Published: July 5, 2017 Content info: 84 Pages
Description

About Peptic Ulcer Drugs

A peptic ulcer is an open lesion, which develops on the mucosal lining of the stomach and the small intestine due to the caustic effect of the gastric acid and pepsin present in these organs. The general symptoms of a peptic ulcer include abdominal pain, nausea, vomiting, and bloated stomach. The specific symptom of peptic ulcer is the bleeding of the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. It is caused mainly by the Helicobacter pylori bacteria followed by the overuse of over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs) like naproxen, aspirin, and ibuprofen.

Technavio's analysts forecast the global peptic ulcer drugs market to grow at a CAGR of 2.80% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global peptic ulcer drugs market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Peptic Ulcer Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca,
  • Daewoong Pharmaceuticals,
  • Eisai,
  • Takeda Pharmaceutical

Other Prominent Vendors

  • GlaxoSmithKline
  • Pfizer

Market driver

  • Economics of treating ulcer
  • For a full, detailed list, view our report

Market challenge

  • Adverse effect of PPIs
  • For a full, detailed list, view our report

Market trend

  • Bismuth-based quadruple therapy
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR13352

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: Peptic ulcers: Disease overview

PART 06: Key clinical trials

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by drug class

  • PPIs
  • Antibiotics
  • Others

PART 09: Geographical segmentation

  • Peptic ulcer drugs market in Americas
  • Peptic ulcer drugs market in EMEA
  • Peptic ulcer drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Bismuth-based quadruple therapy
  • Emergence of monotherapy
  • Recurrent H. pylori infections
  • Rise in awareness

PART 13: Vendor landscape

  • Competitive scenario

PART 14: Key vendor analysis

  • AstraZeneca
  • Daewoong Pharmaceuticals
  • Eisai
  • Takeda Pharmaceutical
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Types of peptic ulcer
  • Exhibit 02: Global peptic ulcer drugs market: Pipeline landscape based on sponsors
  • Exhibit 03: Global peptic ulcer drugs market: Pipeline landscape
  • Exhibit 04: Global peptic ulcer drugs market: List of clinical trials and their aim/purpose
  • Exhibit 05: Snapshot of global peptic ulcer drugs market
  • Exhibit 06: Global peptic ulcer drugs market 2016-2021 ($ millions)
  • Exhibit 07: Opportunity analysis in global peptic ulcer drugs market
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Segmentation of global peptic ulcer drugs market based on drug class 2016
  • Exhibit 10: Global peptic ulcer drugs market share based on drug class 2016
  • Exhibit 11: Global peptic ulcer PPIs drugs market 2016-2021 ($ millions)
  • Exhibit 12: Global peptic ulcer antibiotics drugs market 2016-2021 ($ millions)
  • Exhibit 13: Global peptic ulcer drugs market for others 2016-2021 ($ millions)
  • Exhibit 14: Segmentation of global peptic ulcer drugs market based on geography 2016 and 2021
  • Exhibit 15: Segmentation of global peptic ulcer drugs market revenue based on geography 2016-2021
  • Exhibit 16: Segmentation of global peptic ulcer drugs market based on geography 2016-2021 (%)
  • Exhibit 17: Market scenario in Americas
  • Exhibit 18: Peptic ulcer drugs market in Americas 2016-2021 ($ millions)
  • Exhibit 19: Market scenario in EMEA
  • Exhibit 20: Peptic ulcer drugs market in EMEA 2016-2021 ($ millions)
  • Exhibit 21: Market scenario in APAC
  • Exhibit 22: Peptic ulcer drugs market in APAC 2016-2021 ($ millions)
  • Exhibit 23: Age-related proportion of patients with duodenal and gastric ulcer
  • Exhibit 24: Some of the marketed combination products
  • Exhibit 25: Revenue erosion of Pariet after loss of exclusivity
  • Exhibit 26: Competitive structure analysis of global peptic ulcer drugs market 2016
  • Exhibit 27: AstraZeneca: Key highlights
  • Exhibit 28: AstraZeneca: Strength assessment
  • Exhibit 29: AstraZeneca: Strategy assessment
  • Exhibit 30: AstraZeneca: Opportunity assessment
  • Exhibit 31: Daewoong Pharmaceuticals: Key highlights
  • Exhibit 32: Daewoong Pharmaceuticals: Strength assessment
  • Exhibit 33: Daewoong Pharmaceuticals: Strategy assessment
  • Exhibit 34: Daewoong Pharmaceuticals: Opportunity assessment
  • Exhibit 35: Eisai: Key highlights
  • Exhibit 36: Eisai: Strength assessment
  • Exhibit 37: Eisai: Strategy assessment
  • Exhibit 38: Eisai: Opportunity assessment
  • Exhibit 39: Takeda Pharmaceutical: Key highlights
  • Exhibit 40: Takeda Pharmaceutical: Strength assessment
  • Exhibit 41: Takeda Pharmaceutical: Strategy assessment
  • Exhibit 42: Takeda Pharmaceutical: Opportunity assessment
Back to Top